Patents by Inventor Zhicai Wu

Zhicai Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potassium channel inhibitors
    Patent number: 7879839
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Douglas C. Beshore, B. Wesley Trotter, Kausik K. Nanda, Richard Isaacs, Linda S. Payne, Lou Anne Neilson, Zhicai Wu, Mark T. Bilodeau, Peter J. Manley, Adrienne E. Balitza
  • SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20100227845
    Abstract: The present invention relates to compounds represented by Formula (I), Formula (II) and Formula (III) and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: October 14, 2008
    Publication date: September 9, 2010
    Inventors: Zhicai Wu, John C. Hartnett
  • Inhibitors of Akt activity
    Patent number: 7750151
    Abstract: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: July 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark T. Bilodeau, Chixu Chen, Nicholas D. P. Cosford, Brian W. Eastman, John C. Hartnett, Essa H. Hu, Peter J. Manley, Lou Anne Neilson, Lida R. Tehrani, Zhicai Wu
  • DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20100099673
    Abstract: The present invention relates to compounds represented by Formula (I): and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: January 11, 2008
    Publication date: April 22, 2010
    Inventors: Mark T. Bilodeau, Nathan R. Kett, Craig Lindsley, Peter J. Manley, Jeffrey Y. Melamed, Daniel Vincent Paone, B. Wesley Trotter, Zhicai Wu
  • IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20090325936
    Abstract: The present invention relates to compounds represented by Formula (I) and Formula (II): (I) (II) or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: December 14, 2007
    Publication date: December 31, 2009
    Inventors: Mark T. Bilodeau, Christopher S. Burgey, Zhengwu James Deng, Nathan R. Kett, Jeffrey Melamed, Peter M. Munson, Kausik K. Nanda, Wayne Thompson, B. Wesley Trotter, Zhicai Wu, John C. Hartnett
  • Inhibitors of Akt activity
    Patent number: 7638530
    Abstract: The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: December 29, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Zhicai Wu
  • Inhibitors of Akt activity
    Patent number: 7579355
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: August 25, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Duggan, John C. Hartnett, Craig W. Lindsley, Zhicai Wu, Zhijian Zhao
  • Potassium channel inhibitors
    Patent number: 7569589
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Christopher J. Dinsmore, Jeffrey M. Bergman, B. Wesley Trotter, Lou Anne Neilson, Zhicai Wu, Peter Manley, John Hartnett
  • Inhibitors of Akt activity
    Patent number: 7544677
    Abstract: The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 9, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Nicholas D. P. Cosford, John C. Hartnett, Yiwei Li, Jun Liang, Peter J. Manley, Lou Anne Neilson, Tony Siu, Zhicai Wu
  • Potassium Channel Inhibitors
    Publication number: 20090069312
    Abstract: The present invention relates to dipyridin-3-ylmethoxy compounds and derivatives thereof having the structure I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: January 29, 2007
    Publication date: March 12, 2009
    Inventors: B. Wesley Trotter, Richard C.A. Isaacs, Zhicai Wu, Jacob M. Hoffman, Mark T. Bilodeau, Ahren Iver Green
  • Potassium Channel Inhibitors
    Publication number: 20090030043
    Abstract: The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: January 29, 2007
    Publication date: January 29, 2009
    Inventors: Jacob M. Hoffman, Anthony M. Smith, John Hartnett, Zhicai Wu, Mark T. Bilodeau
  • Inhibitors of Akt Activity
    Publication number: 20080280899
    Abstract: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: April 5, 2005
    Publication date: November 13, 2008
    Inventors: Mark T. Bilodeau, Chixu Chen, Nicholas D.P. Cosford, Brian W. Eastman, John C. Hartnett, Essa H. Hu, Peter J. Manley, Lou Anne Neilson, Lida R. Tehrani, Zhicai Wu
  • Inhibitors of Akt activity
    Patent number: 7414055
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: August 19, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Craig W. Lindsley, Zhicai Wu, Zhijian Zhao, John C. Hartnett
  • Potassium Channel Inhibitors
    Publication number: 20080090794
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: July 27, 2005
    Publication date: April 17, 2008
    Inventors: Christoph Dinsmore, Jeffrey Bergman, Douglas Beshore, B. Wesley Trotter, Kausik Nanda, Richard Isaacs, Linda Payne, Lou Anne Neilson, Zhicai Wu, Mark Bilodeau, Peter Manley, Adrianne Balitza
  • Inhibitors of Akt Activity
    Publication number: 20070254901
    Abstract: The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: August 19, 2005
    Publication date: November 1, 2007
    Inventors: Mark Bilodeau, Nicolas Cosford, John Hartnett, Yiwei Li, Jun Liang, Peter Manley, Lou Neilson, Tony Siu, Zhicai Wu
  • Inhibitors of Akt activity
    Patent number: 7223738
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: May 29, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Duggan, John C. Hartnett, Craig W. Lindsley, Peter J. Manley, Zhicai Wu, Zhijian Zhao
  • Inhibitors of akt activity
    Publication number: 20070043001
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: April 20, 2004
    Publication date: February 22, 2007
    Inventors: Mark Bilodeau, Mark Duggan, John Hartnett, Craig Lindsley, Zhicai Wu, Zhijian Zhao
  • Inhibitors of akt activity
    Publication number: 20060270673
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: April 20, 2004
    Publication date: November 30, 2006
    Applicant: MERCK & CO., INC.
    Inventors: Mark Duggan, Craig Lindsley, Zhicai Wu, Zhijian Zhao, John Hartnett
  • Tyrosine kinase inhibitors
    Patent number: 7125888
    Abstract: The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Zhicai Wu
  • Inhibitors of akt activity
    Publication number: 20060205765
    Abstract: The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: April 20, 2004
    Publication date: September 14, 2006
    Applicant: MERCK & CO., INC.
    Inventors: Mark Bilodeau, Zhicai Wu